Advances in graft-versus-host disease biology and therapy
By B. Blazar, W. Murphy, M. Abedi. Nature reviews. Immunology, 2012
849 citations recorded by the source corpus.
Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders, but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past decade has brought impressive advances in our understanding of the role of stimulatory and suppressive elements of the adaptive and innate immune systems from both the donor and the host in GVHD pathogenesis. New insights from basic immunology, preclinical models and clinical studies have led to novel approaches for prevention and treatment. This Review highlights the recent advances in understanding the pathophysiology of GVHD and its treatment, with a focus on manipulations of the immune system that are amenable to clinical application.
Subfields: Hematology, Immunology
View Paper: https://www.semanticscholar.org/paper/23f0e7b0489e3d8f0b35325df095a77c00d4a311
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. (2016, background): “Advances in our understanding of chronic GVHD have established that both T and B cells, interacting in a highly complex network, contribute to tissue injury and the varied clinical manifestations of chronic GVHD (3, 4).”